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Endogenous digitalis—like factors in hypertension and chronic renal
insufficiency. Endogenous digitalis—like factors have been implicated in
the adaptations that accompany renal insufficiency and in the pathogen-
esis of hypertension. We recently described several fractions of normal
human plasma that inhibit NaK-ATPase and exhibit apparent digoxin—
like immunoreactivity. To determine if hypertension and/or renal insuf-
ficiency affect plasma levels of these factors, we examined four patient
groups: normotensive controls; hypertensive subjects with normal renal
function; hypertensives with moderate renal insufficiency; and chronic
dialysis patients. Plasma levels of digoxin—like immunoreactivity and
NaK-ATPase inhibitory activity were significantly increased in hyper-
tensive patients with mild renal failure (7.6 1.1 ouabain equivalents,
mean SEM, N = 21 vs 4.1 1.1 in normotensive controls, N = 20, P
<0.05). NaK-ATPase inhibitory activity tended to be higher in patients
with primary hypertension and normal renal function (5.5 0.7 ouabain
equivalents, P < 0.07); in dialysis patients, it was not different from
controls. There was no correlation between NaK-ATPase inhibitory
activity and blood pressure in any group. There was a significant rise in
plasma NaK-ATPase inhibitory activity during dialysis (+ 1.8 0.7
ouabain equivalents, N = 22, P < 0.03). As we have found that
NaK-ATPase inhibitory activity in the plasma of normal humans can be
separated into three distinct fractions, El1, El2, and El3, we analyzed
the plasma of 10 dialysis patients further. The increase in NaK-ATPase
inhibitory activity could be attributed to fractions El1 and El3. These
results suggest that plasma NaK-ATPase inhibitors increase with
chronic renal insufficiency, but not hypertension alone. Although
hemodialysis may acutely ralse plasma levels, long—term dialysis re-
turns them to the normal range.
Endogenous inhibitors of the sodium pump have been impli-
cated in the pathogenesis of primary hypertension and in the
physiologic adaptation to chronic renal failure [1—7]. Two
different lines of evidence have suggested that there are plasma
factors capable of inhibiting NaK-ATPase activity. Firstly,
some investigators have shown that leukocyte or erythrocyte
ouabain—sensitive cation flux is depressed in patients with
primary hypertension or chronic renal failure; it also has been
shown that plasma or urine from these patients or from animals
with some forms of experimental hypertension directly inhibit
NaK-ATPase [8—20]. Secondly, inhibitors of NaK-ATPase have
been isolated from human plasma and urine, and from tissues of
experimental animals [21—301. The biologic importance of these
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inhibitors is unknown. It also is unknown whether any of these
inhibitors are ligands for the cardiac glycoside binding site on
NaK-ATPase.
We have recently identified four distinct fractions in the
plasma of normal humans that have many properties of the
cardiac glycosides, including immunoreactivity with digoxin—
specific antibodies [311. Three of the fractions reversibly inhibit
NaK-ATPase activity, reduce ouabain—sensitive monovalent
cation flux in erythrocytes, and prevent binding of radiolabeled
cardiac glycosides to the enzyme. However, in vitro analysis
revealed that these compounds do not act as simple competitive
ligands for the cardiac glycoside binding site nor do they act
specifically on NaK-ATPase. Consequently, it is not clear that
inhibitors in these plasma fractions are physiologically relevant
modulators of sodium pump function in vivo.
To address this question, we have quantified NaK-ATPase
inhibitory activity and digoxin—like inimunoreactivity in desalt-
ed, deproteinized plasma extracts from normotensive control
subjects and from hypertensive patients with and without
chronic renal insufficiency. In addition, we studied how
hemodialysis changed plasma levels of these compounds.
Methods
Four groups of adults were studied: Group I, 20
normotensive subjects with no history of hypertension; Group
II, 20 patients with primary hypertension and normal renal
function; Group III, 21 hypertensive patients with moderate
chronic renal insufficiency; Group IV, 22 patients with
end—stage renal insufficiency studied before and immediately
following hemodialysis. The clinical characteristics of the four
groups are outlined in Table 1. Most patients in the two groups
with chronic renal failure required anti-hypertensive therapy.
Single drug therapy with either nifedipine (five patients) or
aipha—methyldopa (four patients) was used in nine of the
dialyzed patients; the remainder were treated with a combina-
tion of beta—blockers, sympatholytics, or vasodilators. Most
patients in the group with hypertension and moderate renal
insufficiency were treated with a diuretic in combination with a
vasodilator, beta—blocker, or sympatholytic. Twelve of the 20
patients in the primary hypertensive group were untreated at
the time of study; no patient in this group, whether treated or
untreated, had a mean blood pressure below 100 mrs Hg. Mean
blood pressure was calculated as the sum of the diastolic and
one—third of the pulse pressure.
723





Patients with primary hypertension
N — 20
Group III:
Patients with chronic renal failure
(not dialyzed)N = 21
Group IV:




9.2 0.r 220 31.6 Pre: 100.5 2.9°
Post: 89.6 5.0
Plasma fractionation
The techniques previously used to identify and characterize
fractions from normal human plasma that contain digoxin—like
immunoreactivity and NaK-ATPase inhibitory activity [311
have been modified to improve the isolation procedure. Plasma
from patients and control subjects was heated at 80°C for 20
minutes, centrifuged at 35,000 g for 60 minutes, and the
supernatant was desalted using a preparative C15 resin column
(Waters, Milford, Massachusetts, USA), The concentrations of
sodium and potassium in the subsequent solutions were always
less than 10 and 0.5 m, respectively; calcium, magnesium and
vanadium were undetectable by atomic absorption spcctros-
copy. The desalted plasma extracts were ultrafiltered by cen-
trifugation through Amicon YM-2 membranes (Centrifree
Amicon; Danvers, Massachusetts, USA). The ultrafiltrate was
assayed for digoxin—like immunoreactivity and corresponds to
the chromatographic fraction we have previously designated as
1R1. The material retained on the filter was resuspended in 50%
acetonitrile in water, lyophilized, redissolved in water, and
assayed in the 3H-ouabain radioreceptor assay.
In analyzing the plasma of 10 dialysis patients, an aliquot of
the material retained on the filter was fractionated using a 3.9
mm X 37 cm phenylpropylsilane HPLC column (zBondapak
Phenyl, Waters) and eluted with a step—gradient program of
increasing concentrations of acetonitrile in water. Three chro-
matographic fractions, designated El1, El2, and El3, were
identified using the radioreccptor assay.
The recovery of factors with endogenous cardiac glycosidc—
like activity was tested in two ways. First, the recoveries of
radiolabeled cardiac glycosides or linoleic acid added to the
plasma of control and pre-dialysis chronic renal failure patients
was measured. These radiolabeled compounds were chosen
because the cardiac glycosides differ in hydrophobicity and
protein binding characteristics. Linoleic acid was chosen be-
cause recent reports and our own preliminary observations
suggest that at least a portion of the NaK-ATPase inhibitory
activity in plasma may be due to non-esterified fatty acids.
Aliquots of plasma supernatant, SepPak eluate, or material
filtered and retained by the ultrafiltration membrane were
removed and the radioactivity determined by scintillation
counting. Secondly, aliquots of known amounts of digoxin—like
immunoreactivity or NaK-ATPasc inhibitory activity were
added to the plasma supernatant (obtained by heating) from
control subjects and patients with end—stage renal insufficiency.
The spiked supernatants were applied to SepPaks and Amicon
ultrafiltration membranes, and the percent recovery of biologic
activity was determined.
Radioimmunoassay
Polyclonal and monoclonal digoxin—specific antibodies were
used to assay for digoxin—like immunoreactivity. The standard
assay used rabbit polyclonal anti-digoxin antibodies (RIANEN,
New England Nuclear; Bedford, Massachusetts, USA) that had
been prereacted with an anti-rabbit immunoglobulin IgG. This
assay detected fraction JR1 with the same sensitivity as other
polyclonal and monoclonal antisera [311. Deproteinized ultrafil-
trates of plasma were preincuhated for two hours at room
temperature in tubes containing 4 mg/ml of human globulin as a
nonspecific carrier protein (Sigma; St. Louis, Missouri, USA),
0.1 M Tris-Cl buffer (pH 7.4) and rabbit anti-digoxin antibody at
a concentration that bound 30% of 10 nCi of '251-digoxin. The
final reaction volume was 0.95 ml. After the preincubation, 10
nCi of 1251-digoxin in 50 Ed were added and incubated for an
additional 20 minutes, and then the tubes were centrifuged at
2,000 g for 10 minutes. The supernatant was discarded and the
bound radioactivity was determined by scintillation counting.
With this technique, we could detect less than 1.0 pg/mI of
digoxin, and the assay was log—linear between S and 50 pg/mI.
Radioreceptor assay
We have found that both NaK-ATPase inhibition and a
3H-ouabain radioreccptor assays yield equivalent measures of
the cardiac glycoside—like activity in plasma [3lj. This was
confirmed for fractions with NaK-ATPase inhibitory activity
from uremic patients, as well as from normal plasma. Hence,
only the 3H-ouabain radioreceptor assay was used to quantify
the enzyme inhibitory activity in the present study. After
deproteinizing and ultrafiltering the plasma, material retained
on the ultrafiltration membrane was lyophilized, resuspended in
water and an aliquot was added to media containing 25 Ed of 0.6
mg/ml canine kidney cortex NaK-ATPase (Sigma) in 100 mrs
NaCl, 50 mivi Tris-CI (pH 7.4), 0.25 mM Na2EDTA, 5 mM




Table 1. Demographic and clinical characteristics of subjects in each group
Age Sex Mean BP
8 Female 1 Black 1.0 0.1 153 - 12.7 87 4.9
12 Male 19 White
6 Female 2 Black 1.1 0.1 143 -t 26.6 110.7 3.9°
14 Male 18 White
8 Female 0 Black 5.1 + 0.7° 197 27.9 106 3.4°
13 Male 21 White
63.5 4.2° 14 Female° I Black
8 Male 21 White
Values are mean + 5EM. a p < 0.05 compared to normotensive control subjects in Group I.
-
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a shaking water bath at 37°C, 0.4 tCi of 3H-ouabain (18
Cilmmol) were added and incubated for another 20 minutes.
The final volume was 1 ml. The reaction was stopped by adding
3 ml of ice—cold buffer and filtering through glass fiber filters.
After washing the filters with 6 ml of ice—cold incubation buffer,
the 3H-ouabain—NaK-ATPase enzyme complex retained on the
filter was measured by liquid scintillation spectrometry. Spe-
cific binding was calculated by measuring the 3H-ouabain bound
in the presence and absence of 1 m unlabeled ouabain. The
amount of 3H-ouabain binding activity present in each plasma
sample is expressed as pmoles of ouabain—like activity per ml.
This method yields only an approximation of the relative molar
quantities of the endogenous inhibitors present because the
concentration—effect curves for ouabain and each of the plasma
fractions with cardiac glycoside—like activity are not strictly
parallel [31].
Values are presented as mean SEM and analyzed by
Student's t-test and analysis of variance. Results were consid-
ered significant at P < 0.05.
Results
The possibility that differences in recovery of endogenous
cardiac glycoside—like activity might lead to systemic errors in
analysis was examined by measuring the recoveries of radiola-
beled ouabain, digoxin, digitoxin, and linoleic acid after each
fractionation step. The recovery of these labeled compounds
from the plasma of four control subjects and five chronically
uremic, pre-dialysis patients following protein precipitation by
boiling was never higher than approximately 40% and was
highly variable. During the SepPak desalting (step 2) and
ultrafiltration procedures (step 3), the recovery was highest for
ouabain and lowest for digitoxin. There were no statistically
significant differences in the recovery of any of these tracers
between control (Group I) and chronically uremic (Group IV)
subjects (Table 2).
We also measured the recovery of endogenous digoxin—like
immunoreactivity and enzyme inhibitory activity directly.
Known amounts of both forms of activity were added to
deproteinized plasma supernatants from four Group I subjects
and five Group IV chronic renal failure patients. These samples
of plasma supernatant were then desalted (step 2) and
ultrafiltered (step 3). The recovery of the digoxin—like immuno-
reactivity following both steps was approximately 80%. The
recovery of enzyme inhibitory activity was less, averaging 57%.
For both types of biologic activity, the percent recoveries from
plasma supernatants of control or chronic renal failure subjects
did not differ statistically. Based on the recovery of both labeled
compounds and biologic activity, the amount of digoxin—like
immunoreactivity and NaK-ATPase inhibitory activity was
always standardized to the volume of supernatant obtained
from deproteinizing plasma after step 1.
In Figure 1 are shown the amounts of digoxin—like immuno-
reactivity in Groups Ito IV patients. Digoxin—like immunoreac-
tivity was significantly higher in Group III patients with hyper-
tension and moderate renal insufficiency (18.6 2.6 pg/ml
digoxin equivalents; P < 0.005) than in either 20 control
subjects (7.2 2.5 pglml) or 22 Group II hypertensive subjects
with normal renal function (8.4 1.1 pglml). To determine the
effects of hemodialysis on levels of digoxin—like immunoreac-
tivity, we also examined plasma samples from 22 Group IV
Dialysis
Fig. I. Digoxin—like immunoreactivity was measured in deproteinized,
desalted plasma samples from normotensive controls (C) and three
patients groups: patients with primary hypertension (HTN); patients
with hypertension and moderate chronic renal insufficiency (HTN/
CRF); and chronically hemodialyzed patients (samples were obtained
both before [Pre] and after [Post] hemodialysis). Symbol is: * P < 0.05
compared to normotensive controls.
patients obtained immediately before and after dialysis.
Digoxin—like immunoreactivity was not elevated in this group of
patients nor was it increased significantly by dialysis (8.7 1.4
pglml and 11.2 2.7 pg/mi, respectively). The changes with
dialysis in plasma immunoreactivity for individual patients are
shown in Figure 2A. The one patient with a high pre-dialysis
value (36 pglml) was a 93-year-old woman; she also had the
largest increase in plasma levels of NaK-ATPase inhibitory
activity. There were no significant correlations in any group
between levels of digoxin—like immunoreactivity and blood
pressure, or serum creatinine; the type of anti-hypertensive
therapy did not appear to have any effect on the results. The
apparent plasma digoxin—like immunoreactivity in these pa-
tients is the same as that previously described as fraction JR1
and is distinct from plasma fractions containing NaK-ATPase
inhibitory activity [31].
Previously, we found that measuring the NaK-ATPase inhib-
itory activity in plasma gave the same results as measuring
ouabain displacing activity. We confirmed that this was the case
for plasma samples from uremic subjects as well. Since the
ouabain displacing assay is similar, we have used it to examine
NaK-ATPase inhibitory activity in plasma. As shown in Figure
3, Group III patients with moderate renal insufficiency and
hypertension had significantly higher (P < 0.05) levels of factors
that displaced ouabain from NaK-ATPase (7.6 1.1 nmol/liter
ouabain equivalents) compared to Group I control subjects (4.1
1.1 nmol/liter). Group II patients with primary hypertension
had a level that was intermediate between Groups I and III (5.5
0.7 nmol ouabain equivalents/liter; P < 0.07 compared to
Group I). Chronically dialyzed patients had plasma levels of
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P < 0.001) that were significantly lower than Group III patients
with moderate renal insufficiency and hypertension. However,
plasma levels rose with dialysis in 17 of 22 patients (Fig. 2B),
resulting in a significant increase to 3.7 0.7 nmol ouahain
equivalents/liter (P C 0.02 by paired i-test). There were no
significant correlations between plasma levels of NaK-ATPase
inhibitory activity and age, blood pressure, or triglyceride level
in Groups I to III. There was, however, a weak correlation
between NaK-ATPase inhibitory activity and both pre- (r =
0.48) and post- (r = 0.54) dialysis values of mean blood
pressure. There was no correlation between weight loss during
dialysis (mean weight loss 1.7 0.2 kg) and changes in
plasma NaK-ATPase inhibitory activity. Because the Group IV
dialysis patients were demographically dissimilar to Group III
patients with moderate renal insufficiency, we used analysis of
variance to examine the independent effects of age and sex on
levels of digoxin—like immunoreactivity and NaK-ATPase in-
hibitory activity in all patients with renal disease. There was no
independent effect of sex or age on plasma levels of either form
of digitalis—like activity in both groups. in contrast, there was a
highly significant effect of chronic hemodialysis therapy on both
digoxin—like immunoreactivity (P C 0.005) and NaK-ATPase
inhibitory activity (P C 0.001).
In order to determine which individual plasma fractions with
enzyme inhibitory activity (El1, El2, El3) rose with dialysis,
desalted plasma extracts from 10 dialysis patients who had an
increase in plasma ouabain—like activity were fractionated using
a reverse phase phenylpropylsilane HPLC column 3lJ. As
shown in Figure 4, significant increases occurred in fractions
El1 (from 30.1 7.2% to 70.5 86%, P C 0.05) and El3 (3.9
3.7% to 68.5 11.7 %, P C 0.01). Although levels of inhibitory
activity in fraction El2 also tended to rise, the results varied
considerably, and on the average the rise was not statistically
significant.
Discussion
In this study, we have determined that plasma levels of
digoxin—like immunoreactivity and NaK-ATPase inhibitory ac-
tivity are elevated in hypertensive patients with moderate
chronic renal insufficiency (Figs. I and 3), compared to two
demographically similar groups with normal renal function,
normotensive subjects and patients with primary hypertension.
Although the plasma level of NaK-ATPase inhibitory activity
tended to be higher in hypertensive patients with normal renal
function compared to normotensive subjects, the difference was
not quite statistically significant (P C 0.07). Within Groups Ito
III, there was no correlation between the severity of the
hypertension or the degree of renal insufficiency and plasma
levels of either digoxin—like immunoreactivity or NaK-ATPase
inhibitory activity. The absence of a correlation in these groups
may be due to differences in treatment regimens, even though






























Fig. 2. The effects of hemodialysis on levels of
(A) digoxin—like immunoreactivity, and (B)
NaK-ATPase inhihitaty activity in plasma of
chronically dialyzed patients obtained
immediately before and after a dialysis
treatment. NaK-ATPase inhibitory activity
rase in 17 of 22 patients (P C 0.02 by paired
I-test); the change in digoxin—like
Pre-dialysis Post-dialysis immunoreactivity was not significant.
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0
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CRF Dialysis
Fig. 3. NaK-ATPase inhibitory activity was measured in deproteinized,
desalted plasma samples from normotensive controls (C) and three
patient groups: patients with primary hypertension (HTN); patients
with hypertension and moderate chronic renal insufficiency (HTN/
CRF); and chronically hemodialyzed patients before and after dialysis.
Plasma levels were significantly (* P < 0,05) higher in the HTN/CRF
group, and tended to be higher in the hypertensive group (P < 0.07).
Dialysis induced a significant (P < 0.02) rise in plasma inhibitory
activity.
study. Another possible explanation is that we measured the
total activity rather than the free, non-protein bound level of
NaK-ATPase inhibitors. We have not been able to measure
unbound levels of NaK-ATPase inhibitors reproducibly be-
cause they adsorb to ultrafiltration and dialysis membranes.
We also examined the effects of chronic hemodialysis on
plasma levels of cardiac glyco side—like activity. In these Group
IV patients, levels of digoxin—like immunoreactivity were sig-
nificantly less than in hypertensive patients with moderate renal
insufficiency (Fig. 1), and on the average, plasma immunoreac-
tivity did not change with dialysis (Fig. 2A). However, levels of
plasma NaK-ATPase inhibitory activity were lower in patients
before dialysis than in undialyzed, Group III patients (Fig. 4).
Importantly, the average plasma level of inhibitory activity
increased significantly during dialysis (Fig. 3), rising in 17 of 22
patients (Fig. 2B). As illustrated in Figure 4, levels of enzyme
inhibitory activity in fractions El1 and El3 increased signifi-
cantly during dialysis; the increase in fraction El2 was not
significant. Even though the dialysis patients were not strictly
comparable demographically to the other patient groups, anal-
ysis of the effects of age and sex on plasma NaK-ATPase
inhibitory activity still revealed that there was an independent
effect of chronic hemodialysis therapy on the pre-dialysis level
of plasma NaK-ATPase inhibitory activity. Likewise, there was
an independent effect of chronic hemodialysis therapy on
plasma immunoreactivity. A lower value for NaK-ATPase
inhibitory activity is consistent with previous reports that the
Fraction El1 Fraction El2 Fraction El3
Fig. 4. Plasma NaK-ATPase inhibitory activity in patients with pre- and
post-hemodialysis. Plasma extracts were fractionated into fractions
El1, El2 and El3 using phenyipropylsilane reverse phase HPLC [31].
abnormality in erythrocyte sodium pump function improves
with long—term dialysis therapy [321. All patients in Group IV
had been dialyzed for more than two months.
On the other hand, the rise in NaK-ATPase inhibitory activ-
ity during dialysis was unexpected, since Smith and Welt [33]
and Izumo et a! [34] showed that ouabain sensitive 86Rb influx
into erythrocytes improves during dialysis. A possible explana-
tion is that hemodialysis removes substances that compete with
the inhibitors for binding to plasma proteins. In this case, the
rise in total (bound plus unbound) plasma inhibitory activity
might reflect a transfer of the inhibitor from NaK-ATPase to
plasma proteins. If the inhibitory activity were, as suggested by
Tamura et al [35] non-esterified fatty acids, the rise in plasma
levels during dialysis could reflect release of lipids from plasma
membranes, resulting in an amelioration of erythrocyte sodium
pump function.
The search for the identity of sodium pump inhibitors has
occupied many investigators [1—5, 36]. The recently described
atrial natriuretic peptides, although potent, do not inhibit NaK-
ATPase activity [37] and cannot explain the evidence for a
circulating inhibitor of the sodium pump in chronic renal failure
or in response to volume expansion [24—26]. Recent reports
suggest that NaK-ATPase inhibitors may be lipids. For exam-
ple, Tamura et al have shown that at least a portion of the
increased NaK-ATPase inhibitory activity present in the
plasma of volume-expanded hogs could be attributed to oleic
and linoleic acids [37]. Bidard et al concluded that the
"ouabain—like" factors they isolated from the electric organ of
electrophorus electricus were unsaturated, non-esterified fatty
acids [38], and Schwartzman et al reported that cytochrome
P-450 derivatives of arachidonic acid isolated from mammalian
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Table 2. Percent recovery at each preparative step prior to assay for cardiac glycoside—likc activity
1H-Digitoxin '4C-Linoleic Acid
[39]. indeed, micromolar quantities of these arachidonate de-
rivatives were reported by Jacobson and co-workers to inhibit
active sodium transport by rabbit cortical collecting tubules
[40].
Although fatty acids can inhibit NaK-ATPase in vitro, their
importance in the physiologic response to stimuli such as
volume expansion is speculative. There is no evidence that
non-esterified fatty acids in plasma function as specific and/or
high affinity inhibitors of NaK-ATPase. Thus, the relationship
between plasma oleic acid, linoleic acid, and volume expansion
observed by Tamura et al [37] may reflect increased production
of vasodilatory or natriuretic prostaglandins secondary to saline
infusion. Since activation of phospholipase A2 is necessary for
increased prostaglandin production, a release of unsaturated
fatty acids could be due to activation of this enzyme. Alterna-
tively, the rise in plasma levels of free fatty acids might reflect
decreased renal extraction of free fatty acids. This would occur
if energy utilization by the kidney decreased when volume
expansion reduced active sodium transport.
In summary, we found that the digoxin—like immunoreactiv-
ity and NaK-ATPase inhibitory activity present in the plasma of
normal humans [31] is increased in hypertensive patients with
moderate renal insufficiency, but not in chronically dialyzed
patients. Hypertension alone cannot account for these findings.
The increase in NaK-ATPase inhibitory activity during dialysis
does not support the hypothesis that these inhibitors are re-
leased in response to volume expansion [1—31. Until the basis
for differences in plasma levels of NaK-ATPase inhibitors and
their chemical identity arc known, we can only speculate as to
the pathophysiologic importance of these observations.
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